Revance Therapeutics Profit Margin

The latest profit margin for RVNC is -73.46% as of September 2024. That compares with -195.69% in the prior-year period — up 62.5% year over year. That is below the Healthcare sector average of 10.58%. Investors often review this figure alongside Revance Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, RVNC's profit margin moved from -195.69% to -73.46% — a 62.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Revance Therapeutics's valuation or profitability profile.

Against Healthcare companies, RVNC currently prints -73.46% for profit margin, while the sector average sits near 10.58%. That is roughly 794.3% below the sector mean. Large gaps often invite a closer look at Revance Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Revance Therapeutics converts resources into returns. At -73.46%, RVNC may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -195.69% in the prior-year period — up 62.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting RVNC's profit margin (-73.46%), review year-over-year change from -195.69%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.